Overview

* VistaGen fiscal Q2 net loss widens to $19.4 mln from $13.0 mln year-over-year

* R&D expenses increased to $15.9 mln, driven by PALISADE Program costs

* Company expects PALISADE-3 Phase 3 trial results by year-end

Outlook

* VistaGen expects PALISADE-3 trial results by year-end 2025

* PALISADE-4 trial results anticipated in H1 2026

Result Drivers

* R&D EXPENSES - Increase in R&D expenses driven by higher research, development, and contract manufacturing costs for PALISADE Program

* PHASE 3 TRIALS - Completion of randomized portion of PALISADE-3 Phase 3 trial for social anxiety disorder; results expected by year-end

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.54

Q2 Net -$19.42

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Vistagen Therapeutics Inc ( VTGN ) is $13.50, about 69.9% above its November 12 closing price of $4.07

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)